Love Employee/iStock via Getty Images
Shares of Bullfrog AI (NASDAQ:BFRG) shot up 32% in early trading Wednesday after the AI-enabled drug developer announced positive early results from a collaboration on brain research with the Lieber Institute for Brain Development in Maryland.
The research utilized data from over 2,800 brain samples at the institute, with the samples encompassing such mental disorders as schizophrenia, bipolar disorder and major depressive disorder.
Using Bullfrog’s analytics technology, Bullfrog and LIBD were able to cluster subjects based solely on biological data, independent of behavioral diagnoses, the parties said in a statement.
LIBD Director and CEO Daniel Weinberger called the research “an important first step towards personalized medicine in psychiatry.”
The research is part of an agreement announced last year between Bullfrog and LIBD.
Bullfrog went public in February 2023 through an IPO that raised around $8.4M.
